VBL Therapeutics to Present at 29th Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel--(BUSINESS WIRE)-- VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that Dror Harats, M.D., chief executive officer, will present at the 29th Annual J.P. Morgan Healthcare Conference. Dr. Harats’ presentation is scheduled to begin at 11:30 a.m. PST on Tuesday, Jan. 11, 2011 at the Westin St. Francis Hotel in San Francisco.

Dr. Harats is expected to discuss VBL’s business strategy and to provide updates on the clinical progress of the company’s innovative pipeline of first-in-class treatments for immune-inflammatory diseases and cancer. The company recently announced the initiation of a Phase 2 clinical trial of its lead Lecinoxoid drug candidate, VB-201, among patients with elevated hsCRP levels who are currently taking statins.

About VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201 is the company’s lead candidate from this program, currently in Phase 2 clinical development in patients with psoriasis and patients with elevated hsCRP levels. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, a dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is expected to enter Phase 2 clinical trials in early 2011. The company is based in Tel Aviv, Israel. VBL has 70 granted patents and more than 110 patents pending. For more information on the company, please visit www.vblrx.com.



CONTACT:

Pure Communications
Dan Budwick, 973-271-6085
[email protected]

KEYWORDS:   United States  North America  California  New York  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.